JonathanWesleyRiessMD

PubMed

• CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Tran...
  Ebaa Al-Obeidi, Karen Kelly, David R Gandara, Jonathan W Riess> ;JCO Precision Oncology. 2024 Apr 1
• Targeting MEK in non-small cell lung cancer.
  Lara, M., Blakely, C., Riess, J.> ;Current Problems in Cancer. 2024 Feb 9
• A Case of ROS1-Fusion Non-Small Cell Lung Cancer with Acquired BRAF Mutation Developing Unusual Skin Metastasis.
  Firoz, W., Sen, F., Kiuru, M., Huang, V., Riess, J.> ;Clinical Lung Cancer. 2024 Jan 30
• Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
  Singhal, S., Gandara, D., Riess, J.> ;Journal of Thoracic Oncology. 2024 Jan 1
• Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.
  Wang, Y., Peng, G., Gu, J., Gainor, J., Mino-Kenudson, M., Riess, J., Velcheti, V., Hellmann, M., Zhao, H., Schalper, K., Lopez de Rodas, M.> ;Clinical Cancer Research. 2024 Mar 1
• Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
  Wang, K., Du, R., Myall, N., Lewis, W., Uy, N., Hong, L., Skoulidis, F., Byers, L., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M., Gibbons, D., Park, K., R...> ;Journal of Thoracic Oncology. 2024 Mar 1
• Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.
  Gayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, Tianyi Sun, Nicole M Kuderer, David M Aboulafia, Jared D Acoba, Joy Awosika, Ziad Bakouny, Nicole B Balmaceda, Ting ...> ;Elife. 2023 Oct 17
• 2 citations
  Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
  Nobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, Jun Zhang, Jimmy Ruiz, W Jeffrey Petty, Hirva Mamdani, Jonathan W Riess, Jorge Nieva, Jose M Pachecho, Alexander D F...> ;JAMA Oncology. 2023 Dec 1
• Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.
  Andreas M Heilmann, Jonathan W Riess, Margaret McLaughlin-Drubin, Richard S P Huang, Meghann Hjulstrom, James Creeden, Brian M Alexander, Rachel L Erlich> ;The Oncologist. 2024 Feb 2
• Profile Characterization of Biogenic Amines in Glioblastoma Patients Undergoing Standard-of-Care Treatment.
  Orwa Aboud, Yin Liu, Lina Dahabiyeh, Ahmad Abuaisheh, Fangzhou Li, John Paul Aboubechara, Jonathan Riess, Orin Bloch, Rawad Hodeify, Ilias Tagkopoulos, Oliver Fiehn> ;Biomedicines. 2023 Aug 13
• 21 citations
  Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
  Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi H...> ;Cancer Discovery. 2023 Jul 7
• Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
  Ismail M Meraz, Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, RuPing Shao, Renduo Song, Feng Li, Yonathan Lissanu, Huiqin Chen, Min Jin Ha, Qi Wang, Jing Wang, ...> ;Communications Biology. 2023 Jun 6
• Imaging of lung cancer.
  Mohammad H Madani, Jonathan W Riess, Lisa M Brown, David T Cooke, H Henry Guo> ;Current Problems in Cancer. 2023 Apr 1
• 1 citations
  Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
  Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, N...> ;Clinical Cancer Research. 2023 Sep 15
• 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
  Ismail M Meraz, Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, RuPing Shao, Renduo Song, Feng Li, Yonathan Lissanu, Huiqin Chen, Min Jin Ha, Qi Wang, Jing Wang, ...> ;Communications Biology. 2023 May 11
• 12 citations
  Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
  Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Gr...> ;Nature Genetics. 2023 May 1
• 4 citations
  Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.
  Ebaa Al-Obeidi, Jonathan W Riess, Umberto Malapelle, Christian Rolfo, David R Gandara> ;Hematology/oncology Clinics of North America. 2023 Jun 1
• Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.
  Thomas Yang Sun, Brandon Nguyen, Simon B Chen, Yasodha Natkunam, Sukhmani Padda, Matt van de Rijn, Robert West, Joel W Neal, Heather Wakelee, Jonathan W Riess> ;JTO Clinical and Research Reports. 2023 Apr 1
• 11 citations
  Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
  Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina Baik, Mirjana Wollner, Eric B Haura, Hirva Mamdani, Jonathan W Riess, Federico Cappuzzo, Marina C Garassino, Jo...> ;Journal of Thoracic Oncology. 2023 Aug 1
• 2 citations
  Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
  Gayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, Tianyi Sun, Nicole M Kuderer, David M Aboulafia, Jared D Acoba, Joy Awosika, Ziad Bakouny, Nicole B Balmaceda, Ting ...> ;Medrxiv. 2023 Mar 10
• 6 citations
  Osimertinib in NSCLC With Atypical-Activating Mutations: A Retrospective Multicenter Study.
  Jingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, Laura Huppert, Julia K Rotow, Hatim Husain, Susan Stewart, Rosemary Cobb, Heather A Wakelee, Collin M Blakely, M...> ;JTO Clinical and Research Reports. 2023 Mar 1
• 4 citations
  Application of Machine Learning to Metabolomic Profile Characterization in Glioblastoma Patients Undergoing Concurrent Chemoradiation.
  Orwa Aboud, Yin Allison Liu, Oliver Fiehn, Christopher Brydges, Ruben Fragoso, Han Sung Lee, Jonathan Riess, Rawad Hodeify, Orin Bloch> ;Metabolites. 2023 Feb 17
• 1 citations
  Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.
  Matthew S Lara, Matthew A Gubens, Bianca Bacaltos, Lea Daran, Steffany L Lim, Tianhong Li, David R Gandara, Trever G Bivona, Jonathan W Riess, Collin M Blakely> ;JTO Clinical and Research Reports. 2022 Dec 1
• A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement.
  Vasyl Nesteryuk, Omar Hamdani, Raymond Gong, Nava Almog, Brian M Alexander, Steffan Soosman, Ken Yoneda, Siraj M Ali, Alexander D Borowsky, Jonathan W Riess> ;Clinical Lung Cancer. 2022 Dec 1
• 2 citations
  A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer.
  Xing Yi Woo, Anuj Srivastava, Philip C Mack, Joel H Graber, Brian J Sanderson, Michael W Lloyd, Mandy Chen, Sergii Domanskyi, Regina Gandour-Edwards, Rebekah A Tsai, J...> ;Cancer Research. 2022 Nov 15
• Join now to see all

Lectures

• Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance 
  2019 ASCO Annual Meeting - 6/1/2019